Almirall Takes a Leap into Dermatology Digital Health Innovation

AlmirallAlmirall, S.A. (ALM) has launched its first call for innovation to start-ups focused on dermatology digital health. This initiative is the first step in the creation of an accelerator programme called the Digital Garden, powered by Almirall and strengthens the company's commitment to digital innovation based on developing services and solutions to tackle some of the present and future dermatological challenges. The call has been presented during the first Barcelona Health Hub (BHH) Summit, sponsored by Almirall, which has taken place at BHH’s headquarters, located in Barcelona, Spain.

The Digital Garden will begin its journey supporting up to five start-ups chosen after a selection process that will end on November 14th at Almirall's event in Berlin at Frontiers Health 2019, a leading global event on digital health innovation of which Almirall is a sponsor.

Francesca Wuttke, Chief Digital Officer of Almirall, explains the importance of this project "I am so pleased and excited to announce the launch of the Digital Garden powered by Almirall, and to do so at the BHH Summit. In fact, the five start-ups selected during Frontiers of Health will have access to a nine-month acceleration program based in the BHH headquarters, among other important benefits."

Digital Garden's selection process

Interested start-ups can apply at almiralldigitalgarden.com, where they will also find the program's inclusion criteria and offerings. Following a review of the applicants, Almirall will make a shortlist of 10 companies that will be invited to Frontiers Health 2019 to pitch their business models at an Almirall sponsored event that will take place on Thursday 14th of November. The five winning project teams will begin a nine-month acceleration program in January at the BHH headquarters, with the goal of graduating them into venture capital funding. The program will include introductions to investors as well as an investor day.

In addition to the acceleration program, the five chosen start-ups will receive a number of key incentives, including up to a €50K grant that is determined based on a bespoke gap analysis of the start-up and achievement of certain milestones. In addition, they will receive mentoring from top pharma industry experts from all specialties and program stages; and will have the opportunity to leverage leading hospitals in Barcelona as a test bed for digital pilots, with potential access to HCPs and patients; the potential to collaborate on actual Almirall projects; and have access to Almirall's communication and PR networks to promote their projects, among others.

"Embracing technologies to better access data to empower patients"

Francesca Wuttke is one of the four BHH Ambassadors, highly renowned professionals in digital health that are dedicated and aligned with the goals of the Barcelona Health Hub. They are collaborating to increase awareness in digital health and in a global recognition of the BHH. During the BHH Summit 2019, she moderated one of the panels entitled "Embracing technology to better access data to empower patients". CEOs from three of the start-ups that are sharing BHH co-working space have discussed growing trends in the pharmaceutical industry. Increasingly, pharma companies are collaborating with start-ups to improve the strength of their data and bring efficiencies with regard to time and cost. The panellists have also shared their views about the potential of new technologies in the era of Real World Data and Real World Evidence, the impact of regulation and the future of partnerships between big companies and start-ups with its implicit challenges and lessons learned.

According to Francesca Wuttke, "Medical dermatology is a representative example of the potential of patient centric digital health. The Digital Garden, powered by Almirall can be seen as a case study of both the recent and rapid development in this space and the huge potential of this new digital revolution in medicine."

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions where they are needed.

The company, founded almost 75 years ago and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its shareholders and its decision to help others by understanding their challenges and using Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. Almirall has more than 1,800 employees.

Most Popular Now

ChatGPT can Produce Medical Record Notes…

The AI model ChatGPT can write administrative medical notes up to ten times faster than doctors without compromising quality. This is according to a new study conducted by researchers at...

Alcidion and Novari Health Forge Strateg…

Alcidion Group Limited, a leading provider of FHIR-native patient flow solutions for healthcare, and Novari Health, a market leader in waitlist management and referral management technologies, have joined forces to...

Can Language Models Read the Genome? Thi…

The same class of artificial intelligence that made headlines coding software and passing the bar exam has learned to read a different kind of text - the genetic code. That code...

Study Shows Human Medical Professionals …

When looking for medical information, people can use web search engines or large language models (LLMs) like ChatGPT-4 or Google Bard. However, these artificial intelligence (AI) tools have their limitations...

Advancing Drug Discovery with AI: Introd…

A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field...

Bayer and Google Cloud to Accelerate Dev…

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will...

Shared Digital NHS Prescribing Record co…

Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed...

Ask Chat GPT about Your Radiation Oncolo…

Cancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers? A new Northwestern Medicine study tested a specially designed ChatGPT...

Wanted: Young Talents. DMEA Sparks Bring…

9 - 11 April 2024, Berlin, Germany. The digital health industry urgently needs skilled workers, which is why DMEA sparks focuses on careers, jobs and supporting young people. Against the backdrop of...

North West Anglia Works with Clinisys to…

North West Anglia NHS Foundation Trust has replaced two, legacy laboratory information systems with a single instance of Clinisys WinPath. The trust, which serves a catchment of 800,000 patients in North...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...

AI Makes Retinal Imaging 100 Times Faste…

Researchers at the National Institutes of Health applied artificial intelligence (AI) to a technique that produces high-resolution images of cells in the eye. They report that with AI, imaging is...